Match!
Clinical Cancer Research
IF
8.91
Papers
21136
Papers 10000
1 page of 1,000 pages (10k results)
Newest
#1Nicholas C. Turner (The Royal Marsden NHS Foundation Trust)H-Index: 45
#2Claire Swift (The Breast Cancer Research Foundation)
Last. Martine Piccart-Gebhart (ULB: Université libre de Bruxelles)H-Index: 110
view all 15 authors...
PURPOSE ESR1 mutations are acquired frequently in hormone receptor positive (HR+) metastatic breast cancer after prior aromatase inhibitors (AI). We assessed the clinical utility of baseline ESR1 circulating tumor DNA analysis in the two phase III randomised trials of fulvestrant versus exemestane. PATIENTS AND METHODS The phase III EFECT and SoFEA trials randomised patients with HR+ metastatic breast cancer who had progressed on prior non-steroidal AI, between fulvestrant 250mg and exemestane. ...
Source
One of the key contributors to the failure of oncology trials is patient selection bias. A bias that results in a lower observed efficacy in phase II may lead to a premature decision to abort a trial, whereas a bias in the positive direction may result in an expensive failure in phase III. We propose an approach in which RWE is used to model a proxy endpoint that is available in RWE but is also related to the endpoint in clinical trial, on patient profile; the model is then used on clinical tria...
Source
#1Ezra Y. Rosen (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
#2Debra A. Goldman (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 21
Last. James P. Solomon (Cornell University)H-Index: 1
view all 16 authors...
TRK inhibitors achieve marked tumor-agnostic efficacy in TRK fusion-positive cancers and consequently are now an established standard of care. Little is known, however, about the demographics, clinical outcomes, response to alternative standard therapies, or genomic characteristics of TRK fusion-positive cancers. Utilizing a center-wide screening program involving more than 26,000 prospectively sequenced patients, genomic and clinical data from all cases with identified TRK fusions were extracte...
Source
#1Molly E. Heft Neal (UM: University of Michigan)
#2John H. Owen (UM: University of Michigan)H-Index: 11
Last. Steven B. Chinn (UM: University of Michigan)H-Index: 11
view all 6 authors...
Background: The tumor microenvironment (TME) is made up of epithelial cancer cells and mesenchymal stromal cells including tumor-infiltrating lymphocytes, cancer-associated fibroblasts (CAFs) and endothelial cells. Within the cancer cell population are cancer stem cells (CSC), a subpopulation of cells defined as having the capacity for self-renewal, tumorigenesis, and the ability to recapitulate a heterogeneous tumor. The interaction of the TME with cancer cells remains of interest. The focus of...
Source
#1Anthony Bolyos (U of C: University of Calgary)
#2Pinaki Bose (U of C: University of Calgary)H-Index: 13
Among head and neck squamous carcinoma (HNSC), human papilloma virus (HPV)-driven tumors are known to enjoy more favorable prognostic outcomes compared to non-HPV-driven disease. This is especially true of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), which is associated with significantly improved outcomes compared to HPV-positive non-OPSCC and HPV-negative HNSC. Previous reports have suggested that increased immune infiltration and expression of the estrogen receptor α (ERα) may ...
Source
#1Clint T. Allen (NIH: National Institutes of Health)H-Index: 12
#2Jay Friedman (NIH: National Institutes of Health)H-Index: 14
Last. Ravi Uppaluri (Harvard University)H-Index: 22
view all 4 authors...
Induction of T-cell responses to immunorecessive tumor antigens may be important for generation of polyclonal responses capable of eliminating immunoedited tumor cells that have lost immunodominant antigens. We hypothesized that neoadjuvant PD-1 mAb immune checkpoint inhibition (ICI) before surgery could induce polyclonal T-cell responses and lead to immunologic memory capable of preventing engraftment upon challenge with tumor cells lacking immunodominant antigen. Antigen immunodominance was es...
Source
#1Karson J. Kump (UM: University of Michigan)H-Index: 1
#2Matthew L. Lieberman (UM: University of Michigan)
Last. Dale Bixby (UM: University of Michigan)H-Index: 20
view all 14 authors...
Effective practice of precision medicine in oncology relies on identifying and targeting unique characteristics of individual cancers. Coupling functional analysis with genomic screening will further enhance the selection of efficacious cancer therapies. Cancer is a heterogeneous disease that is defined by distinct capabilities, one of which is the evasion of apoptosis, controlled by the antiapoptotic protein members, Bcl-2, Bcl-xL, Mcl-1, and Bfl-1. These antiapoptotic proteins have become vali...
Source
#1Lyudmila Bazhenova (UCSD: University of California, San Diego)H-Index: 28
#2Xiaolong Jiao (Bayer AG: Bayer HealthCare Pharmaceuticals)
Last. Marc Mardoche Fellous (Bayer AG: Bayer HealthCare Pharmaceuticals)H-Index: 2
view all 10 authors...
Introduction: The neurotrophic tyrosine receptor kinase (NTRK) genes NTRK1, 2, and 3 have emerged as oncogenic drivers, and their resultant tropomyosin receptor kinase (TRK) proteins are targets for precision medicines. Larotrectinib, a selective TRK inhibitor, and entrectinib, a multikinase inhibitor, have been approved for patients (pts) with TRK fusion cancer. This study was conducted to evaluate the molecular characteristics and prognosis of TRK fusion cancer in a real-world setting. Methods...
Source
#1Guo Yu (Genome Institute of Singapore)
#2Zhong Wee Poh (Genome Institute of Singapore)
Last. Anders J. Skanderup (Genome Institute of Singapore)H-Index: 4
view all 7 authors...
Our understanding of mutations in noncoding DNA is still nascent across most cancer types. Similarly, the potential clinical utility of noncoding DNA in cancer liquid biopsy assays remains mostly unexplored. Here, we identify high-frequency noncoding mutation hotspots in whole genomes from hundreds of gastrointestinal tumors and show that these mutations can be detected in liquid biopsy samples from cancer patients. We demonstrate how profiling of noncoding mutation hotspots can significantly in...
Source
#1Amarbir S. Gill (UC Davis: University of California, Davis)H-Index: 1
#2Michael R. Kinzinger (UC Davis: University of California, Davis)H-Index: 1
Last. Michael G. Moore (UC Davis: University of California, Davis)H-Index: 13
view all 3 authors...
Purpose: 1. To understand practice patterns among head and neck surgeons and radiation oncologists in the assessment and management of malnutrition in head and neck cancer patients. 2. To identify barriers that prevent the identification of and intervention upon malnutrition. Background: Among patients who undergo surgery for head and neck cancer, there is a strong association between severe malnutrition and increased postoperative complications, length of stay, and cost of care. We aim to evalu...
Source
12345678910
Top fields of study
Cancer
Immunology
Cancer research
Medicine
Biology